In-Clinic Canine Cancer Test Launched in US, Europe through Veterinary Diagnostics Company Antech

Listen to this article

VolitionRx Limited, a multi-national epigenetics company, recently announced that its Nu.Q Vet Cancer Test is now available in-clinic to veterinarians across the U.S and Europe through Antech, a leading veterinary diagnostics company.

Antech’s in-clinic version of the Nu.Q Canine Cancer Test operates on the Element i+ Analyzer, providing veterinarians with a rapid, accurate and cost-effective cancer screening tool for high-risk breeds and older dogs, at the patient side, with results in about six minutes.

Dr Tom Butera, CEO of Volition Veterinary Diagnostics Development LLC, said: “Through this collaboration, our groundbreaking Nu.Q® technology is now available to veterinarians across the U.S. and Europe, enabling vital canine cancer screening and providing in-clinic results within minutes. By incorporating the Nu.Q Canine Cancer Test into annual checkups or regular senior wellness exams, veterinarians can detect cancer¹ earlier and help pet owners make timely, informed decisions about cancer care.”

Volition’s original license and supply agreement was between Belgian Volition SRL and Heska, an Antech company, part of Mars Science & Diagnostics.

Dr Butera added: “Antech’s rollout of the Nu.Q Canine Cancer Test marks a huge step forward for Volition as we seek to fulfil our mission of ensuring our epigenetic technology is accessible and affordable worldwide, to detect and monitor disease earlier and improve outcomes.”

Volition is a multi-national epigenetics company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis such as sepsis.

[1] Wilson-Robles, H.M., Bygott, T., Kelly, T.K. et al. Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Vet Res 18, 329 (2022).

• According to The Veterinary Cancer Society,  one in four dogs will be diagnosed with cancer, and it’s the leading cause of death in pets who are beyond middle age.
• Approximately 190 million dogs in the U.S. (source) and Europe (source)